Michigan's ReCODE+ Residential Program
Michigan Cognitive Recovery Center is a 20-suite, 24/7 residential program inside Lakeshore Woods Senior Living in Fort Gratiot, Michigan. MCRC offers the 12-month ReCODE+ For Facilities Program™ in partnership with Apollo Health for appropriate participants with subjective cognitive impairment, mild cognitive impairment, or early-stage Alzheimer’s disease. A clinical assessment is required before enrollment.
7.4M
Americans with Alzheimer's
202,800
Michigan Alzheimer's Patients
84%
of Participants Showed Cognitive Improvement
30+
Years of Bredesen Research
The Problem
For decades, Alzheimer’s disease has been treated as progressive and untreatable. Mainstream medicine offers drugs that may slow decline, but over 400 clinical drug trials have failed to produce a real solution.
The average lifetime cost of Alzheimer’s care exceeds $400,000 per patient. Yet no standard treatment addresses the underlying biochemical drivers of cognitive decline.
Dr. Dale Bredesen’s research at Apollo Health, built on over 30 years of laboratory science, challenges this assumption — identifying more than 36 individual contributors to cognitive decline that can each be addressed through a personalized precision medicine approach.
36+
Identified contributors to cognitive decline
Evidence from Apollo Health Clinical Research
84% of participants in recent clinical trials showed measurable improvement in cognitive function using the ReCODE protocol.
Published results from Apollo Health’s clinical research, including the 2025 randomized controlled trial, showed measurable cognitive improvement in many participants with mild cognitive impairment or early-stage Alzheimer’s. Every person is different — individual results vary, and no outcome can be guaranteed. A clinical assessment is required before enrollment, and this program is not a substitute for care from a licensed physician.
The Science
The ReCODE Protocol was developed by Dr. Dale Bredesen, an internationally recognized expert in neurodegenerative disease at Apollo Health. Rather than treating Alzheimer’s with a single drug, ReCODE identifies and addresses each individual patient’s unique biochemical contributors to cognitive decline.
2014 · Peer-Reviewed Publication
Dr. Bredesen’s landmark paper demonstrating measurable cognitive improvement in patients for the first time using a multi-factor precision medicine approach. Published in a peer-reviewed medical journal.
2022 · Clinical Trial Results
Published in the Journal of Alzheimer’s Disease. The first clinical trial where each patient was evaluated individually and treated with a personalized precision medicine protocol.
2025 · Randomized Controlled Trial
The 2025 RCT demonstrated statistically and clinically significant improvements in cognition and depression symptoms in participants with mild to moderate Alzheimer’s disease.
Published results from Apollo Health’s clinical research, including the 2025 randomized controlled trial, showed measurable cognitive improvement in many participants with mild cognitive impairment or early-stage Alzheimer’s. Every person is different — individual results vary, and no outcome can be guaranteed. A clinical assessment is required before enrollment, and this program is not a substitute for care from a licensed physician.
The Program
Full baseline evaluation identifying each resident’s specific contributors to cognitive decline — the foundation of your personalized ReCODE report.
An individualized treatment plan generated through Apollo Health’s precision medicine platform, targeting your specific biochemical drivers of decline.
Structured learning covering the full ReCODE protocol: nutrition, sleep optimization, exercise, stress management, and metabolic health.
Sessions focused on real-world protocol application, cooking training, behavior change strategies, and personalized challenges.
Apollo Health’s KetoFLEX 12/3 brain-optimized nutrition protocol, prepared by our culinary team and tailored to each resident’s dietary needs.
Learn more about how KetoFLEX 12/3 works within the ReCODE Protocol™.
Regular cognitive and lab re-testing with protocol adjustments as each resident’s health evolves throughout the 12-month program.
Full residential care within Lakeshore Woods’ Birch Building, Fort Gratiot, MI, supported by trained dementia care staff around the clock.
$11,500
per month · 12-month program
The average lifetime cost of Alzheimer’s care exceeds $400,000. A full 12-month MCRC program ($138,000) represents approximately one-third of that, with a protocol designed to address underlying drivers of decline — not simply manage symptoms.
Approximately 40,000 Michigan residents with Alzheimer’s may be financially qualified for this program.
Our team will discuss candidacy, the application process, and financial options on your call.
Our Locations
NOW OPEN
📍 Fort Gratiot, Michigan
Michigan’s first ReCODE+ residential program, now open and accepting residents. Operating in partnership with Apollo Health. Located within Lakeshore Woods senior living community on Lake Huron’s shoreline.
COMING SOON
📍 Fenton, Michigan
Coming soon — bringing the ReCODE+ For Facilities Program™ in partnership with Apollo Health to Metro Detroit and Flint-area families. The Fenton Woods location will dramatically expand access to this program within Michigan.
The Researcher
“Treating Alzheimer’s is analogous to repairing a roof with 36 holes. The more holes you cover, the more success you have at fixing the problem.”
Dr. Dale Bredesen is an internationally recognized expert in the mechanisms of neurodegenerative diseases and a professor at UCLA. His over 30 years of laboratory research, resulting in hundreds of peer-reviewed publications, has fundamentally changed how we understand and approach cognitive decline.
In 2014, Dr. Bredesen disrupted mainstream medicine with a peer-reviewed publication demonstrating cognitive improvement in patients — the first time such results had been documented. His continued work through Apollo Health has produced a 100-patient case study series, a 2022 clinical trial, and a 2025 Randomized Controlled Trial.
Michigan Cognitive Recovery Center operates as a ReCODE+ partner of Apollo Health, implementing Dr. Bredesen’s protocol in a full residential setting.
A Personal Dedication
“This program is dedicated to my brother.”
When Alzheimer’s began changing my brother, our family experienced the same fear, confusion, and uncertainty that so many families face. Every day felt like navigating the unknown, without clear answers or a path forward.
What overwhelmed us most was the lack of structure. Families are often left guessing, trying to piece together information, searching for solutions, and hoping they are making the right decisions.
The Michigan Cognitive Recovery program at Lakeshore Woods was created to bring together science, structure, and compassionate care — a program designed not only to support families, but to give them clarity, stability, and a guided path forward.
This work is deeply personal to me, and to our entire team. Every family that walks through our doors deserves hope, understanding, and the confidence that they are not facing this journey alone.
Steven Larsen, Founder and CEO of Lakeshore Woods and Michigan Cognitive Recovery Center
Candidacy
The ReCODE+ program is best suited for individuals in earlier stages of cognitive decline, where the protocol has shown the greatest measurable outcomes in published research.
Subjective Cognitive Impairment (SCI) — early self-reported memory concerns without objective deficits
Mild Cognitive Impairment (MCI) — measurable cognitive changes that do not yet significantly affect daily function
Early-Stage Alzheimer’s Disease — diagnosed early Alzheimer’s with function intact enough to engage with the protocol
Families seeking a proactive, evidence-based approach rather than a wait-and-manage strategy
Individual outcomes vary, and improvement or reversal is not guaranteed. We offer a comprehensive, individualized, precision medicine residential program that has shown measurable outcomes in published peer-reviewed studies at Apollo Health.
We welcome questions about the evidence and are prepared to share peer-reviewed publications with families and referring physicians.
The 2025 Randomized Controlled Trial showed statistically and clinically significant improvements in cognition and depression in participants with mild cognitive impairment or early dementia. Individual outcomes vary. This program is not a substitute for evaluation and ongoing care by a licensed physician.
From Our Blog
Evidence-based guidance for families navigating Alzheimer’s and cognitive decline. Updated regularly by our clinical team.
You came home for Thanksgiving expecting familiar routines. Then something felt different. Maybe your mother asked the same question several times during dinner. Maybe your father became confused in a house he has visited for years. Maybe bills were piled unopened on the counter. Maybe the refrigerator looked unusually empty.…
When a parent is diagnosed with Alzheimer’s disease, one of the first private questions an adult child may ask is: “Does this mean I am going to get Alzheimer’s too?” The fear becomes even stronger when families begin reading about APOE4, genetic risk, and inherited forms of Alzheimer’s. A parent’s…
A 12-month residential cognitive recovery program is a significant commitment. Families are not only asking what happens during the program. They are also asking: What happens after Month 12? Does the participant return home? Can they remain at Lakeshore Woods? Which parts of the ReCODE Protocol continue? Does testing continue?…
Spots Available Now
The Vineyards in Fresno, California — the only other active ReCODE+ residential program in the United States — is at capacity. Michigan Cognitive Recovery Center at Lakeshore Woods has availability today. Don’t wait.
